Methanesulfonic acid 2-ethoxy-4-formyl-phenyl ester

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: Methanesulfonic acid 2-ethoxy-4-formyl-phenyl ester
• 英文别名: (2-ethoxy-4-formylphenyl) methanesulfonate
• 化学式: C₁₀H₁₂O₅S
• mdl: MFCD13874057
• 分子量: 244.268
• InChiKey: HTYSZVHRFXGDIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  78
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  乙基香兰素 、 甲基磺酰氯 在 4-二甲氨基吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以100%的产率得到Methanesulfonic acid 2-ethoxy-4-formyl-phenyl ester
  参考文献：
  名称：

  Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives

  摘要：

  这项发明涉及以下式的化合物 其中A、B 1 、B 2 、R 1 、R 2 和G如描述和索赔中所定义，并其药学上可接受的盐。该发明还涉及含有这种化合物的药物组合物，以及用于制备它们的方法和它们用于治疗和/或预防与调节SST受体亚型5相关的疾病的用途。

  公开号：

  US20060205718A1

文献信息

• Pyrimidine, quinazoline, pteridine and triazine derivatives
  申请人：Binggeli Alfred

  公开号：US20070225271A1

  公开（公告）日：2007-09-27

  This invention is concerned with compounds of the formula wherein A, R 1 to R 5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  这项发明涉及以下式的化合物 其中A，R1至R5和G如描述和声明中所定义，并其药学上可接受的盐。该发明还涉及含有这种化合物的药物组合物，以及用于制备它们的方法和它们用于治疗和/或预防与调节SST受体亚型5相关的疾病的用途。
• Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives
  申请人：Binggeli Alfred

  公开号：US20060205718A1

  公开（公告）日：2006-09-14

  This invention is concerned with compounds of the formula wherein A, B 1 , B 2 , R 1 , R 2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  这项发明涉及以下式的化合物 其中A、B 1 、B 2 、R 1 、R 2 和G如描述和索赔中所定义，并其药学上可接受的盐。该发明还涉及含有这种化合物的药物组合物，以及用于制备它们的方法和它们用于治疗和/或预防与调节SST受体亚型5相关的疾病的用途。
• Pyrimidine and quinazoline derivatives
  申请人：Christ Andreas D.

  公开号：US20080045550A1

  公开（公告）日：2008-02-21

  This invention is concerned with compounds of the formula wherein A, R 1 to R 5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  本发明涉及以下式子的化合物，其中A，R1到R5和G的定义如描述和权利要求中所述，并且其药学上可接受的盐。本发明还涉及含有这些化合物的制药组合物，以及其制备过程和用于治疗和/或预防与SST受体亚型5调节相关的疾病的用途。
• Pyrimidine and Quinazoline Derivatives
  申请人：Christ Andreas D.

  公开号：US20100069413A1

  公开（公告）日：2010-03-18

  This invention is concerned with compounds of the formula wherein A, R 1 to R 5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  本发明涉及公式中的化合物，其中A、R1至R5和G如描述和权利要求中所定义，并且其药学上可接受的盐。本发明还涉及含有这些化合物的药物组合物，以及制备它们的过程和它们用于治疗和/或预防与SST受体亚型5调节相关的疾病的用途。
• Substituted piperidine derivatives as SST5 modulators
  申请人：Hoffmann-La Roche Inc.

  公开号：US07968568B2

  公开（公告）日：2011-06-28

  This invention is concerned with compounds of the formula wherein A, R1 to R5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  本发明涉及以下式子的化合物，其中A，R1到R5和G的定义如说明书和权利要求所述，并且其药学上可接受的盐。本发明还涉及包含这些化合物的药物组合物，以及制备它们的过程和它们用于治疗和/或预防与SST受体亚型5调节相关的疾病的用途。